AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016
AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, on 3-7 June 2016.
Click on this link for more information.
